Fundz

Cloverleaf Bio reported raising $14.8 Million in an initial SEC Form D filing, from an offering of $29.6 Million

PRIVATESep 08, 2026

Amount Raised

$14.8 Million

$14.8 Million sold, per SEC Form D (first sale Aug 24, 2026)
$33 Million per company press release (Sep 8, 2026)

Round Type

Seed

New HavenBiotechnologyHealth CareMedicalTherapeutics

Investors

Eli Lilly And CompanyAbbVie VenturesMission BioCapitalAmerican Cancer Society BrightEdge4BIO CapitalBoehringer Ingelheim Venture FundDraper Associates

Description

Cloverleaf Bio has successfully closed a $33 million Seed financing round to support the development of its RNA-based cancer therapies. The round was led by 4BIO Capital and included significant investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund. These funds will help advance two lead programs targeting hepatocellular carcinoma and colorectal cancer. The strong participation from pharmaceutical investors underscores interest in Cloverleaf's scientific platform.

Who to call at Cloverleaf Bio, and when

A new round usually means Cloverleaf Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cloverleaf Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cloverleaf Bio, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cloverleaf Bio

Location

New Haven, Connecticut, United States

About

Cloverleaf Bio is an RNA therapeutics company focused on developing a new class of engineered transfer RNA (tRNA) based payloads for cancer treatment. Their platform is designed to inhibit multiple RNA-modifying enzymes that cancer cells depend on for proliferation. The company is advancing two lead programs targeting hepatocellular carcinoma and colorectal cancer. Cloverleaf aims to bring innovative cancer treatments from the lab to clinical settings.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cloverleaf Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsCole, Co-Founder hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Cloverleaf Bio's next move

See what Strategic adds

Cloverleaf Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.